In this issue:
Mono or combination chemotherapy for elderly patients with advanced nonsquamous NSCLC
Pembrolizumab for untreated metastatic nonsquamous NSCLC
Long-term outcomes for pembrolizumabtreated, PD-L1 positive, advanced NSCLC patients
Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors
PD-L1 expression and durvalumab for stage III NSCLC
Neoadjuvant sintilimab in NSCLC
Immune checkpoint inhibitors for lung sarcomatoid carcinoma
Weekly paclitaxel plus bevacizumab for advanced non-squamous NSCLC
Statins and risk of lung cancer in COPD patients
Afatinib for NSCLC harboring uncommon EGFR mutations
Please login below to download this issue (PDF)